CYTO-NK-202

N/A

Report date: 2022/09/01 11:16:39

Base Information

Drug NameCYTO-NK-202

Drug Alias NameCYTO-NK-202

ClassificationCell and gene therapy > Cell therapy > Immune system cell therapy > Lymphocytes therapy > Natural killer cell therapy > Chimeric antigen receptor NK cell therapy

Mechanisms of ActionImmunologic cytotoxicityNatural killer cell replacements

TargetsNot applicable

Therapy Area/IndicationsHematologic Neoplasms

Global Approved IndicationsN/A

Approved Indications in ChinaN/A

Original Approved Country/TerritoryN/A

Original Approved DateN/A

Country/TerritoryUnited States

CombinationsNo

Global Highest StatusPreclinical

Highest Status in ChinaN/A

Originator CompaniesCytoImmune Therapeutics Inc

China Registration ClassN/A

Develop Information

Active CompaniesCytoImmune Therapeutics Inc

Inactive CompaniesN/A

Active IndicationsHematologic Neoplasms

Inactive IndicationsN/A

Other Information

ATC CodeN/A